The Company was founded in 1999 based on this observation. Two non-psychoactive cannabinoids are in the development pipeline.
A New Paradigm in the Treatment and Prevention of HIV disease
Our drugs target the immune response rather than the virus by activating the peripheral cannabinoid receptors leading to a quiescent state which is unfavorable for HIV transmission and replication.
Two patents have been issued based on results of the results of a NIH R21 grant completed in May of 2016. An article is in preparation for publication showing that both of our non-psychoactive cannabinoids increase the barrier function of a vaginal tissue construct. The results suggest that the oral delivery of the drug will be more effective than a topical application which will result in lower costs and increased compliance. The lead drug proved to be stable in metabolic studies.
That in the context of a global need for HIV prevention and treatment, the cost of our drugs will not be a barrier to their use. Our goal is to bring the drug to the developing world at a cost of 10¢ or less per day. We will continue to find ways to bring the costs down.